GelMEDIX Inc. is an early-stage biotechnology company leveraging its hydrogel platform to develop ocular and regenerative therapies that can restore vision. GelMEDIX was founded after multiple years of fruitful academic collaboration between our co-founders Reza Dana (Mass. Eye And Ear, Harvard Med. School) and Nasim Annabi (UCLA).  Our proprietary photo-crosslinked hydrogels uniquely enable bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading across modalities from small molecules to cell and gene therapies. Our lead program is an integrated hydrogel cell therapy designed to restore vision for macular degeneration patients with Dry AMD and GA.